Results 281 to 290 of about 3,239,691 (384)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Where did the attack come from? The mysterious case of paralysis mimicking Guillain-Barré syndrome: Case report. [PDF]

Medicine (Baltimore)
Wagner W, Krawiec M, Iwanicki A, Krupa P, Gębka-Kępińska B, Lubiński M, Białka S.   +6 more
europepmc   +1 more source

People \u2013 history \u2013 politics. Russian perceptions of Poland and Germany. Key conclusions [PDF]

, 2012
Gromadzki, Grzegorz et al.
core  

The Role of Periarticular Knee Muscle Torques in Ensuring the Body Balance of Older Adults with Balance Disturbances. [PDF]

J Clin Med
Prochor P, Magnuszewski Ł, Zalewska P, Świętek M, Wojszel ZB, Piszczatowski S.   +5 more
europepmc   +1 more source

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis

ESC Heart Failure, EarlyView.
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch, Christine Pausch, Doerte Huscher, David Pittrow, Judith Wede, Fabian Kreimendahl, Stephan Rosenkranz, Stephan Beckmann, Matthias Held, Ekkehard Grünig, H. Ardeschir Ghofrani, Hans Klose, Andris Skride, Michael Halank, Stefan Stadler, Marion Delcroix, Anton Vonk‐Noordegraaf, Ralf Ewert, Grzegorz Kopec, Marius M. Hoeper, Karen M. Olsson   +20 more
wiley   +1 more source

Supragingival plaque microbiota and caries risk factors among children with mixed dentition. [PDF]

BMC Oral Health
Opydo-Szymaczek J, Torlińska-Walkowiak N, Maćkowiak K, Mizgier M, Pacholak K, Olejnik-Schmidt A, Schmidt M, Śniatała R.   +7 more
europepmc   +1 more source

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure (HF) is one of today's leading public health issues worldwide. The sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin recently received a label expansion. It is now approved for treatment of HF across the entire spectrum of ejection fraction (EF) in Germany. However, real‐world data are limited.
Matthias Paul, Ralph Bosch, Behrus Subin, Angelika Guth, Marlena Mueller, Mareike Seelinger, Stephanie Riemann, Birgit Assmus   +7 more
wiley   +1 more source

Management of neonatal ovarian cysts: a 10-year single-center experience. [PDF]

Pediatr Surg Int
Szymon O, Fryczek M, Kotlarz A, Taczanowska-Niemczuk A, Górecki W.   +4 more
europepmc   +1 more source

What Will We Learn if We Start Listening to Women with Menses-Related Chest Pain? [PDF]

J Clin Med
Marjanski T, Czapla A, Niedzielska J, Grono L, Bobula J, Świątkowska-Stodulska R, Milnerowicz-Nabzdyk E.   +6 more
europepmc   +1 more source